Close Menu

NEW YORK – PerkinElmer said after the close of the market on Tuesday that its second quarter revenues grew 12 percent year over year as Diagnostics segment revenues were up 46 percent.

For the three months ended July 5, the company reported total revenues of $811.7 million compared to $722.5 million a year ago. It beat the consensus Wall Street estimate of $726.4 million.

Organically, revenues rose 13 percent year over year, PerkinElmer CFO Jamey Mock said on a conference call following the release of the financial results.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.